Medical Oncology

ITP

Questions discussed in this category

How does your management of ITP change when related to CLL?

What if there is continued thrombocytopenia despite reaching complete remission (with incomplete marrow recovery)?

2 Answers available

What are your top takeaways in Classical Hematology from ASH 2024?

9 Answers available

How do you approach very treatment-refractory ITP?

Such as the case in which a patient is unresponsive to steroids, IVIG, TPO-agonist, rituximab, splenectomy, and even fostamitinib.

1 Answer available

At what platelet count would you feel comfortable dosing aspirin 81 mg for coronary artery disease in a patient with ITP?

Presuming strong indication for ASA - eg history of NSTEMI

1 Answer available

For treatment of ITP, what would you add to dexamethasone to achieve the fastest recovery in a patient waiting for a procedure?

IVIG, TPO, or other agents?

1 Answer available

Are there any reasons to consider a prolonged course of steroids with taper over a shorter course of pulsed steroids in the treatment of ITP?

For example, do we prefer one regimen over the other in patients with a bleeding history or who have relapsed after a lengthy remission?

1 Answer available

How do you approach the treatment of ITP in a pregnant patient who did not respond to prednisone?

Would you consider high-dose dexamethasone (deliberating adverse effects of antenatal steroids) or move to next-line therapies?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2013-02-21

Apixaban for extended treatment of venous thromboembolism.

The New England journal of medicine, 2017 Mar 18

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Related Topics in Medical Oncology